Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug

Zevra Therapeutics, Inc. (ZVRA) announced that the FDA has indicated that it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee ("GeMDAC") to review the company's new drug application (NDA) for pipeline candidate arimoclomol. NPC is an ultra-rare, progressive, and neurodegenerative lysosomal storage disorder characterized by an inability of the body to transport cholesterol and other lipids within the cell, leading to an accumulation of these substances in various ...